3天内可长满;细胞形态特性:上皮样;细胞生长特性:贴壁生长;细胞背景资料:RKO是一个低分化的结肠癌细胞系。RKO细胞含有野生型P53,但缺乏人甲状腺受体核受体(h-TRbeta1)。RKO细胞的P53蛋白的水平高于RKO-E6细胞。RKO细胞系是RKO-E6和RKO-AS45-1的亲本细胞系。该细胞系在裸鼠中成瘤,且在软琼脂中形成集落。
C-33A细胞系;细胞传代方法:1:2-1:3传代;每周换液2-3次;细胞形态特性:上皮细胞样;细胞生长特性:贴壁;细胞背景资料:该细胞系由Auersperg N建立,源于宫颈癌活检标本。p53 +,pRB +,在273位密码子发生点突变。乳头状瘤病毒DNA、RNA阴性。 Primary Epidermal Keratinocytes细胞系;细胞传代方法:1:2-1:3传代;每周...
4.蟾毒灵能够上调P53及其下游靶分子Bax和P27表达. 5.蟾毒灵能抑制MMP-2,COX-2表达,而对MMP-3,MMP-9表达未见明显影响,提示我们蟾毒灵抑制肝癌细胞侵袭转移和抑制MMP-2有更密切的关系. 6.成功构建了原位移植裸鼠人肝癌转移模型LCI-D20,在肝癌转移裸鼠模型中,蟾毒灵可抑制肝癌细胞肺转移和Cdc42蛋白表达; 7....
11.Xiao EH, Li JQ, Huang JF. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.World J Gastroenterol. 2004;10:190-194.[PubMed] 12.Shi YJ, Gong JP, Liu CA, Li XH, Mei Y, Mi C, Huo YY. Construction of a...
STRAP is involved in spliceosomal mRNP assembly in the cytoplasm and pre-mRNA splicing in the nucleus [53]. Overexpression of STRAP was reported in several cancers [53,77]. A STRAP-activated p53-related apoptosis-induction effect and higher expression of STRAP in drug-treated HCC cells were obs...
目的观察中药野菊花提取物(chrysanthemum indicum extact,CIE)对人肝癌MHCC97H细胞增殖和凋亡的影响及其作用机制。方法体外培养人肝癌MHCC97H细胞,以0.4、0.8、1.2 mg/ml的CIE(实验1、2、3组)作用于MHCC97H细胞,并设立空白对照组。分别于药物作用24、48、72 h时,应用MTT法检测细胞增殖情况。于药物作用2...
和抑癌基因 p53、Rb [6] 等的失活。 近年来研 究 [7] 表明表观遗传学的改变亦参与到肝癌发生发 展过程中,如DNA 甲基化修饰、组蛋白修饰等。 组 蛋白甲基化修饰是一种重要的表观遗传学修饰方 式,由组蛋白赖氨酸和精氨酸甲基转移酶所介导,可 调节基因的转录 [8] 。Hamamoto等 [9] 发现H3K4甲 基化SMY...
METHODS: HCC cell lines (HepG2, Hep3B and MHCC97L) and normal liver cell line (L02) with a different p53 status were infected with SG600-IL24 ... XB Xue,CW Xiao,BP Surgery,... - 《World Journal of Gastroenterology》 被引量: 0发表: 2010年 ...
JIB04 induces cell apoptosis via activation of the p53/Bcl2/caspase pathway in MHCC97H and HepG2 cellsdoi:10.3892/OR.2018.6737Weiguo LiaoJie LiuBin LiuXiaojie HuangYongxin YinDe CaiMingyi LiRunzhi ZhuSpandidos Publications
PAK1 gene silencing decreases proliferation of MHCC97-H cells, HepG2 cells and cells in xenograft tumor through the p53/p21 pathway.doi:10.1038/s41434-018-0016-9Gene Therapy